Back to search results

Cortical Excitability in Cyclic Vomiting Syndrome Study

This study is exploring differences in brain activity, specifically "cortical excitability," between people with Cyclic Vomiting Syndrome (CVS) and healthy individuals. Researchers will use a non-invasive method called Transcranial Magnetic Stimulation (TMS) to stimulate the motor cortex and measure muscle responses. They will also record your heart activity (EKG) to see if it impacts these brain measurements. The main goal is to compare these brain activity patterns over multiple study sessions that could last up to 12 months. You may be able to join if you are 18 to 60 years old and have a diagnosis of CVS. This study is currently unclear on its recruitment status and plans to enroll 110 participants.

Study design
This is an interventional study comparing people with Cyclic Vomiting Syndrome to healthy individuals. It plans to enroll 110 participants.
What's involved
You would undergo TMS paired-pulse assessments and have your heart activity (EKG) recorded during multiple study sessions spanning up to 12 months.
Compensation
Not stated in the trial record.
Follow-up
Your brain activity will be measured over multiple study sessions spanning up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05256160

Cortical Excitability in Cyclic Vomiting Syndrome

Recruiting
NAAges 18–60InterventionalBasic science
University of Pittsburgh
~110 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:TMS Paired-Pulse assessment of cortical excitabilityAutonomic activity

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Paired-pulse ratios
Measured over Multiple study sessions spanning up to 12 months

Conditions

Cyclic Vomiting Syndrome

Explore related trials

Cyclical Vomiting

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • David J Levinthal, MD PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Elijah D Wright
[email protected]
412-647-1228
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

diagnosis of CVS

Exclusion

history of CVS (for healthy control population only)
psychosis or altered cognitive status
history of head injury, metal in the skull, stroke, or a history of seizures or a history of syncope (fainting or passing out)
implantable devices, such as a pacemaker or nerve stimulator
current use of the following medications or use of substances which are known to lower the seizure threshold: clozapine (Clozaril), chlorpromazine (Thorazine), amphetamines or methamphetamine, Ecstasy, Ketamine, Angel Dust/PCP, cocaine, or 3 or more alcoholic drinks per day
pregnancy

What this trial measures

  • Paired-pulse ratiosMultiple study sessions spanning up to 12 months

    Percentage Change in Paired Pulse (PP) TMS induced MEP responses with inhibitory or facilitatory stimulation.